2014
DOI: 10.1200/jco.2014.32.15_suppl.e12532
|View full text |Cite
|
Sign up to set email alerts
|

Pattern of metastatic spread and prognosis of breast cancer biologic subtypes.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
8
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(8 citation statements)
references
References 0 publications
0
8
0
Order By: Relevance
“…Tumors of the triple-negative subtype of breast cancer (TNBC; generally corresponding to the “Basal/Basal-like” subtype of patient datasets, determined by PAM50 gene signatures) lack the expression of estrogen receptor α, progesterone receptor and HER2, are highly aggressive and are most likely to recur. Unlike the luminal-A tumors that are characterized by better survival, or the HER2+ tumors, TNBC/basal tumors cannot be treated by receptor-targeted therapies and demonstrate high relapse rates following chemotherapy (14).…”
Section: Introductionmentioning
confidence: 99%
“…Tumors of the triple-negative subtype of breast cancer (TNBC; generally corresponding to the “Basal/Basal-like” subtype of patient datasets, determined by PAM50 gene signatures) lack the expression of estrogen receptor α, progesterone receptor and HER2, are highly aggressive and are most likely to recur. Unlike the luminal-A tumors that are characterized by better survival, or the HER2+ tumors, TNBC/basal tumors cannot be treated by receptor-targeted therapies and demonstrate high relapse rates following chemotherapy (14).…”
Section: Introductionmentioning
confidence: 99%
“…Thus, we hereby use breast malignancy to exemplify the non-conventional effects of the above chemokines in the cancer setting. The different published studies on chemokine roles in breast cancer addressed so far primarily two subtypes of disease: (1) The highly aggressive triple-negative (TNBC) subtype in which the tumors are negative for the expression of hormone receptors and lack HER2 amplification; these tumors commonly develop resistance to chemotherapy; (2) The luminal-A subtype in which the tumors express estrogen/progesterone receptors (but not amplified HER2) and are hormone-responsive; this disease subtype is treated by endocrine therapies and is considered as having the best prognosis out of all breast cancer subtypes (28,29). Of note, some of the aspects are relatively newly investigated, thus not much information is available in breast cancer; in these cases the scope is expanded to other cancer types as well.…”
Section: Introductionmentioning
confidence: 99%
“…The triple-negative subtype of breast cancer (TNBC), which in gene signature studies is often used as a surrogate for the “Basal/Basal-like” subgroup (e.g., in PAM50 analyses), accounts for ~15% of breast cancers. TNBC cells are negative for the expression of type α estrogen receptors, progesterone receptors or amplified HER2; thus, TNBC tumors do not respond to receptor-targeted therapies, and following chemotherapy they are most likely to recur (13). These clinical parameters emphasize the ultimate need for improved understanding of the mechanisms leading to tumor progression in this aggressive subtype of disease.…”
Section: Introductionmentioning
confidence: 99%